cysteine and serine rich nuclear protein 2Genealiases: C12ORF2 · C12orf22 · FAM130A1 · PPP1R72 · TAIP-12
Q-omics provides the consensus-scored CSRNP2 profile across patient tissues and cancer cell-line models. CSRNP2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CSRNP2 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, CSRNP2 RNA expression shows 21,149 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, HNSC, and UVM as cancer lineages where CSRNP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CSRNP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CSRNP2 survival associations across molecular data types. CSRNP2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CSRNP2 RNA expression–survival associations across cancer types. High CSRNP2 expression shows unfavorable associations in ACC, MESO, LIHC, KICH, UVM and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CSRNP2 RNA expression.
This table summarizes CSRNP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CSRNP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CSRNP2 shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, COAD, LUAD and BRCA. The HNSC box plot shows higher CSRNP2 RNA expression in tumor versus normal tissue (log2 FC = +0.931, t-test p < 0.001).
This table shows molecular features associated with CSRNP2 in patient tissues and cancer cell lines. In patient samples, CSRNP2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CSRNP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
